Roche Tecentriq immunotherapy cocktail wins USFDA approval for treating lung cancer

Published On 2019-12-06 03:30 GMT   |   Update On 2019-12-06 03:30 GMT

The U.S. Food and Drug Administration approved Tecentriq mixed with Celgene's Abraxane and carboplatin chemotherapy to treat metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations, Roche said on Wednesday.


New Delhi: Roche's Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb.


Also Read: Tecentriq-Avastin cocktail helps liver cancer patients live longer: Roche


The U.S. Food and Drug Administration approved Tecentriq mixed with Celgene's Abraxane and carboplatin chemotherapy to treat metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations, Roche said on Wednesday.


Read Also: Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020

Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News